Standout Papers
Citation Impact
Citing Papers
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
2006 StandoutNobel
Neutralizing antibody response during acute and chronic hepatitis C virus infection
2004 StandoutNobel
Micro RNA mimicry blocks pulmonary fibrosis
2014
Evidence for a functional RNA element in the hepatitis C virus core gene
2007 StandoutNobel
Mouse models of acute and chronic hepacivirus infection
2017 StandoutScienceNobel
Proteomics of HCV virions reveals an essential role for the nucleoporin Nup98 in virus morphogenesis
2016 StandoutNobel
Hepatitis C virus drug resistance–associated substitutions: State of the art summary
2015
Vitamin E Improves Transplant‐Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis
2018
Vaccination to prevent T cell subversion can protect against persistent hepacivirus infection
2019
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
2018 StandoutNobel
T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?
2014
Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology
2019
Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus
2012
Treatment predictors of a sustained virologic response in hepatitis B and C
2008
SEC14L2 enables pan-genotype HCV replication in cell culture
2015 StandoutNatureNobel
Limitations of non-invasive tests for assessment of liver fibrosis
2020
Treatment of HCV infection with the novel NS3/4A protease inhibitors
2014
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin
2012
HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape
2018
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
2009 StandoutNature
Animal Models for the Study of Hepatitis C Virus Infection and Related Liver Disease
2012
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
2020
Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir
2011
Hepatitis C virus—host interactions, replication, and viral assembly
2012
Treatment triumphs
2014 StandoutNatureNobel
Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy
2017
Serum Cholesterol and Statin Use Predict Virological Response to Peginterferon and Ribavirin Therapy†,‡
2010
Treatment responses in Asians and Caucasians with chronic hepatitis C infection
2008
Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection
2015
Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir
2016
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
2015
Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race
2006
Simeprevir and Sofosbuvir for Treatment of Chronic Hepatitis C Infection
2015
Resistance Analysis of Hepatitis C Virus Genotype 1 Prior Treatment Null Responders Receiving Daclatasvir And Asunaprevir
2013
Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?
2012
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir
2013
Randomized Trial of Peginterferon alfa-2b and Ribavirin for 48 or 72 Weeks in Patients with Hepatitis C Virus Genotype 1 and Slow Virologic Response
2010
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
2013
Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature
2011
New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets
2012
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
2011
Use of Liver Imaging and Biopsy in Clinical Practice
2017
The role of resistance in HCV treatment
2012
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders
2011
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Molecular and cellular mechanisms of liver fibrosis and its regression
2020
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
2014
miRNA–target chimeras reveal miRNA 3′-end pairing as a major determinant of Argonaute target specificity
2015 StandoutNobel
A Human Monoclonal Antibody Targeting Scavenger Receptor Class B Type I Precludes Hepatitis C Virus Infection and Viral Spread In Vitro and In Vivo
2011 StandoutNobel
Non-alcoholic fatty liver disease
2021 Standout
Peginterferon Alfa-2a and Ribavirin in Latino and Non-Latino Whites with Hepatitis C
2009
Pegylated Interferon‐α‐2a plus Ribavirin for Treatment‐Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial
2008
Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations
2015
Antiviral strategies in hepatitis C virus infection
2012
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
2014
Caspase Functions in Cell Death and Disease
2013 Standout
Drug discovery for a new generation of covalent drugs
2012
T cell exhaustion during persistent viral infections
2015
A Broad RNA Virus Survey Reveals Both miRNA Dependence and Functional Sequestration
2016 StandoutNobel
Successes and Challenges on the Road to Cure Hepatitis C
2015
Hepatitis C Virus Subverts Liver-Specific miR-122 to Protect the Viral Genome from Exoribonuclease Xrn2
2014
Treatment of hepatitis C in difficult-to-treat patients
2015
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
2009
Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitors
2014
Update on hepatitis C virus resistance to direct-acting antiviral agents
2014
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
2017 Standout
Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis
2018
Hepatitis C virus and human miR-122: insights from the bench to the clinic
2014
Hepatitis C virus: How genetic variability affects pathobiology of disease
2011
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
2009 StandoutNature
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options
2018
A diverse range of gene products are effectors of the type I interferon antiviral response
2011 StandoutNatureNobel
Therapeutic Landscape for NAFLD in 2020
2020
Hepatitis C Virus-Specific Directly Acting Antiviral Drugs
2013
Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation
2010
Mixing the right hepatitis C inhibitor cocktail
2010
Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
2014
Global control of hepatitis C: where challenge meets opportunity
2013
Toward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond
2020
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
2017 StandoutNobel
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens
2016
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
miRNA independent hepacivirus variants suggest a strong evolutionary pressure to maintain miR-122 dependence
2017 StandoutNobel
From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway
2016
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus
2011
Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C
2014
The FDA-approved drug sofosbuvir inhibits Zika virus infection
2016
Hepatitis C pharmacogenetics: State of the art in 2010
2010
miR-122 Stimulates Hepatitis C Virus RNA Synthesis by Altering the Balance of Viral RNAs Engaged in Replication versus Translation
2015
Past, present and future perspectives in nonalcoholic fatty liver disease
2019
The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus Genotype 1 Infection, But With Issues Still Pending
2011
Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism
2019
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
2014
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
2009
Changes in sequences of core region, interferon sensitivity‐determining region and interferon and ribavirin resistance‐determining region of hepatitis C virus genotype 1 during interferon‐alpha and ribavirin therapy, and efficacy of retreatment
2012
What Are the Promising New Therapies in the Field of Chronic Hepatitis C After the First-Generation Direct-Acting Antivirals?
2012
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
2011 Standout
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection
2016 StandoutNatureNobel
25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end
2013
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
2019
HCV and the hepatic lipid pathway as a potential treatment target
2011
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
2016
Inflammation in obesity, diabetes, and related disorders
2022 Standout
Review article: specifically targeted anti‐viral therapy for hepatitis C – a new era in therapy
2010
Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1–7 and Escape Variants
2017
Hepatitis C Virus RNA Functionally Sequesters miR-122
2015 StandoutNobel
Development of micro RNA therapeutics is coming of age
2014
A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis
2020 StandoutNobel
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles
2003 StandoutNobel
In Vitro Antiviral Activity and Preclinical and Clinical Resistance Profile of Miravirsen, a Novel Anti-Hepatitis C Virus Therapeutic Targeting the Human Factor miR-122
2014
Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients
2015
Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy
2015
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
Therapy for hepatitis C genotype 3: moving forward
2015
Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance
2011
Ultrastructural analysis of hepatitis C virus particles
2013 StandoutNobel
Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients
2013
Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems
2014 StandoutNobel
Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains
2012
Characterization of nonprimate hepacivirus and construction of a functional molecular clone
2015 StandoutNobel
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
2012 StandoutNobel
Modeling hepatitis C virus infection using human induced pluripotent stem cells
2012 StandoutNobel
miRNA Deregulation in Cancer Cells and the Tumor Microenvironment
2016
Precise Modulation of CO2 Sorption in Ti8Ce2–Oxo Clusters: Elucidating Lewis Acidity of the Ce Metal Sites and Structural Flexibility
2024 StandoutNobel
Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications
2015
A bacterial Argonaute with noncanonical guide RNA specificity
2016 StandoutNobel
Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS 5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection
2014
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
2013
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
2020
Cellular cofactors affecting hepatitis C virus infection and replication
2007 StandoutNobel
Aromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent Conjugate
2013 StandoutNobel
The resurgence of covalent drugs
2011
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs
2002 StandoutNobel
Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells
2019 StandoutNobel
Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders
2005 StandoutNobel
Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue
2016 StandoutNobel
Hepatitis C Virus Genotype 5a Subgenomic Replicons for Evaluation of Direct-Acting Antiviral Agents
2014 StandoutNobel
New therapeutic strategies in HCV: second‐generation protease inhibitors
2013
Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T 1 -weighted MRI
2023 StandoutNobel
“Inverse Drug Discovery” Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates
2017 StandoutNobel
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus
2016 StandoutNobel
Importance of HCV genotype 1 subtypes for drug resistance and response to therapy
2014
From NAFLD to MAFLD: Implications of a Premature Change in Terminology
2020
Works of Eric Lawitz being referenced
OP03 Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results: Abstract OP03 Table 1
2011
Sofosbuvir with peginterferon‐ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
2014
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
2017
Levels of Alanine Aminotransferase Confound Use of Transient Elastography to Diagnose Fibrosis in Patients With Chronic Hepatitis C Virus Infection
2012
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
2013
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
2013
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
2018
Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C)
2013
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
2011
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
2009
Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
2013
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
2012
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
2013
Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection
2014
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1.
2015
All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naïve Patients With Genotype 1 HCV Infection
2014
Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients
2008
L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions
2015
DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis
2018
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
2012
A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment
2013
Evaluation of VCH-759 monotherapy in hepatitis C infection
2009
Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis
2013
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis
2017
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure
2013
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial
2012
Effects of Sofosbuvir-Based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C
2013
Differences in treatment outcome for hepatitis C among ethnic groups
2004
Accuracy of Fibroscan, Compared With Histology, in Analysis of Liver Fibrosis in Patients With Hepatitis B or C: A United States Multicenter Study
2014
Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics
2013
The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: A retrospective observational study
2005
Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
2014
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
2010
Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial
2014
Phase 1b Study of Pegylated Interferon Lambda 1 With or Without Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection†
2010
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
2018
The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors
2011
Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis
2019
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
2010
Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis
2015
Treatment of HCV Infection by Targeting MicroRNA
2013 Standout
A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection
2013
1151 CONTINUED HIGH VIROLOGIC RESPONSE RATES WITH ACH-1625 DAILY DOSING PLUS PEGIFN-ALPHA 2A IN A 28-DAY AND 12-WEEK PHASE 2A TRIAL
2012
CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
2019
Characterization of HCV Resistance from a 3-Day Monotherapy Study of Voxilaprevir, a Novel Pangenotypic NS3/4A Protease Inhibitor
2017
All‐oral therapy with nucleotide inhibitors sofosbuvir and GS ‐0938 for 14 days in treatment‐naive genotype 1 hepatitis C (NUCLEAR )
2013
Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885
2013
[783] SHORT-TERM ANTIVIRAL ACTIVITY AND SAFETY OF ACH-806 (GS-9132), AN NS4A ANTAGONIST, IN HCV GENOTYPE 1 INFECTED INDIVIDUALS
2007
Longitudinal changes in liver stiffness by magnetic resonance elastography (MRE), liver fibrosis, and serum markers of fibrosis in a multi-center clinical trial in nonalcoholic steatohepatitis (NASH)
2017
Improvement of hepatic fibrosis and patient‐reported outcomes in non‐alcoholic steatohepatitis treated with selonsertib
2018
O005 : Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks
2015
1186 SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS
2012
LP04 : A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2
2015
P0773 : The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/- RBV
2015
GS‐9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double‐blind, dose‐ranging phase 1 study
2016
1356 QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS
2011
Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein
2016
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)
2015
Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection
2014
Efficacy and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebo-controlled trials
2017
BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: a phase 2 study
2017
1055 ANTIVIRAL ACTIVITY OF ANA598, A POTENT NON- NUCLEOSIDE POLYMERASE INHIBITOR, IN CHRONIC HEPATITIS C PATIENTS
2009
Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients
2012
O006 : C-swift: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks
2015
Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis
2016
1215 PERSISTENCE OF NS5A GS-5885 DRUG RESISTANCE MUTATIONS FOLLOWING 3 DAYS OF MONOTHERAPY IN GENOTYPE-1 HCV PATIENTS IS DEPENDENT ON THE HCV SUBTYPE AND SPECIFIC MUTATION
2012
Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy
2011
273 SHORT TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ACTIVITY OF GS-9450, A SELECTIVE CASPASE INHIBITOR, IN PATIENTS WITH CHRONIC HCV INFECTION
2010
GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)
2019
Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens
2015
1192 VAST MAJORITY OF DETECTED NS5A RESISTANT VARIANTS ARE NOT AMPLIFIED IN HCV PATIENTS DURING 3-DAY MONOTHERAPY WITH THE OPTIMIZED NS5A INHIBITOR PPI-668
2013
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus
2007
622 SAFETY, AND TOLERABILITY OF NIM811, A NOVEL CYCLOPHILIN INHIBITOR FOR HCV, FOLLOWING SINGLE AND MULTIPLE ASCENDING DOSES IN HEALTHY VOLUNTEERS AND HCV-INFECTED PATIENTS
2009
869b Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon-Based Therapy: Results From PROMISE, a Phase III Trial
2013
Analysis of Hepatitis C Viral Kinetics during Administration of Two Nucleotide Analogues: Sofosbuvir (Gs-7977) and Gs-0938
2014